Ernexa Therapeutics (ERNA) Stock
Small biotech company developing early stage therapies. Here's the price, business snapshot, and what's worth knowing about Ernexa Therapeutics in July 2026.
Eterna Therapeutics Inc (ERNA) is a micro‑cap biotechnology company focusing on early‑stage therapeutic development. With a market capitalisation of roughly $9.3 million, it sits in the high‑risk, speculative segment of the market where research progress, financing events and regulatory milestones can drive large price swings. Investors should expect limited liquidity, sparse analyst coverage and the possibility that the company may need to raise capital, which can dilute existing holders. Key things to watch include the status of any clinical or preclinical programmes, intellectual property position, partnerships or licensing deals, and cash runway disclosed in filings. This summary is educational and not personal financial advice — suitability depends on an investor’s risk tolerance, time horizon and portfolio diversification. Because small biotech stocks can be volatile and binary in outcome, consider complementing any research with primary filings and, if needed, a qualified financial adviser.
Stock Performance Snapshot
Financial Health
Ernexa Therapeutics is showing strong cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ERNA
RNA Stocks (M&A Targets) Could See Premium Valuations
Novartis's $12 billion acquisition of Avidity Biosciences underscores the high value of RNA-based treatments for rare diseases. This deal could spark a wave of similar acquisitions, creating opportunities for other biotech companies with innovative RNA platforms.
Published: 27 October 2025
Explore BasketAge-Reversal Biotech
Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early‑stage focus
Company development may centre on preclinical or early clinical work; outcomes can be transformative but are uncertain and timelines may shift.
High volatility risk
Small market capitalisation often brings big price swings and low liquidity; investors should be prepared for rapid gains or losses.
Watch funding events
Financing rounds, partnerships or licensing deals can materially affect prospects and dilution; check filings for cash runway and terms.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
